Bevacizumab (
Avastin(R)) is a
monoclonal antibody against the
vascular endothelial growth factor (
VEGF) receptor that increases the overall
survival rate when added to standard
chemotherapy regimens in
patients with metastatic
colorectal cancer. The known toxicities of
bevacizumab are
hypertension,
proteinuria,
wound healing complications, arterial
thrombosis,
bleeding, and gastrointestinal
complications. Especially
ischemic colitis can rapidly develop into bowel perforation, so an
emergency operation often is needed. Recently, a 65-year-old
male patient developed ischemic pancolitis after FOLFOX (85 mg/m2
Oxaliplatin, d1;200 mg/m2
Leucovorin, d1;400 mg/m2
5-FU iv bolus, d1-2;and 600 mg/m2
5-FU, d1-2, every two wk) and
Bevacizumab combination chemotherapy was administered. However, he recovered after early conservative care without
surgery. We
report this case with a
review of
literature.